Parkinson's Disease (PD) is a progressive neurodegenerative disorder primarily affecting the motor system. Characterized by bradykinesia, rigidity, and resting tremors, PD presents a complex clinical picture that is often challenging to manage.
PD is the second most common neurodegenerative disorder, affecting approximately 1% of individuals over the age of 60. Risk factors include age, male gender, and exposure to certain environmental toxins. Genetic predisposition also plays a role, with several mutations identified.
PD is characterized by the loss of dopaminergic neurons in the substantia nigra, leading to an imbalance in the basal ganglia's output. The exact cause of this neuronal death remains unclear, but it is thought to involve a combination of genetic and environmental factors.
PD typically presents with resting tremor, bradykinesia, and rigidity. Non-motor symptoms such as depression, constipation, and cognitive impairment are also common. Diagnosis is primarily clinical, supported by response to dopaminergic therapy.
Management of PD is symptomatic, with levodopa being the most effective medication for motor symptoms. Non-pharmacological interventions, including physical therapy and deep brain stimulation, may also be beneficial. Regular follow-up is essential to monitor disease progression and adjust treatment accordingly.
PD is a chronic disease with a variable course. Most patients experience a gradual progression of symptoms over many years. Prognosis is influenced by age at onset, severity of symptoms, and response to treatment.
Understanding the complexities of PD is crucial for optimal patient management. As healthcare professionals, we must stay abreast of the latest research to provide the best possible care for our patients with PD.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation